On April 6, the U.S. Food and Drug Administration (FDA) announced it was allowing marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer genetic tests that the FDA as authorized. Read more
Advances in smart pump technology can improve patient safety and provide efficiencies in nursing care delivery. Join our webinar to learn more.